Raffles Medical: More time needed to generate strong returns due to poor performance in China | Lianhe Zaobao

Raffles Medical Group stated at the shareholders' meeting that its performance in China has been poor and requires more time to achieve significant returns. Although the China business accounts for 30% of the group's assets, it only contributes 10% of the revenue. The group pointed out that overseas investments typically take longer to scale and establish clinical capabilities, and the Chinese market is constrained by geopolitical and technological challenges. The Securities and Futures Commission believes that the China business has only increased revenue by approximately 25.4 million yuan over the past seven years, and it is expected to reach 65.4 million yuan by the fiscal year 2025